Caris Life Sciences (CAI) Accounts Payables (2024 - 2026)

Caris Life Sciences' Accounts Payables history runs 3 years deep, the most recent figure standing at $69.8 million for Q1 2026.

• In Q1 2026, Accounts Payables changed N/A year-over-year to $69.8 million; the TTM figure through Mar 2026 stood at $69.8 million (changed N/A YoY), while the FY2025 annual figure was $39.2 million, up 41.07% from the prior year.
• Accounts Payables for Q1 2026 stood at $69.8 million, up from $39.2 million in the prior quarter.
• The five-year high for Accounts Payables was $69.8 million in Q1 2026, with the low at $27.8 million in Q4 2024.
• The 3-year median for Accounts Payables is $29.0 million (2025), against an average of $38.9 million.
• Peak annual rise in Accounts Payables reached 41.07% in 2025, while the deepest fall reached 41.07% in 2025.
• Caris Life Sciences' Accounts Payables stood at $27.8 million in 2024, then jumped by 41.07% to $39.2 million in 2025, then jumped by 78.04% to $69.8 million in 2026.
• Business Quant data shows CAI's Accounts Payables at $69.8 million in Q1 2026, $39.2 million in Q4 2025, and $29.0 million in Q3 2025.